Investment analysts at Oppenheimer assumed coverage on shares of Opko Health (NYSE:OPK) in a note issued to investors on Thursday, Analyst Ratings Network.com reports. The firm set an “outperform” rating on the stock.
Shares of Opko Health (NYSE:OPK) traded down 0.96% on Thursday, hitting $9.32. The stock had a trading volume of 2,367,717 shares. Opko Health has a 1-year low of $6.14 and a 1-year high of $12.95. The stock’s 50-day moving average is $8.56 and its 200-day moving average is $9.3. The company’s market cap is $3.848 billion.
Opko Health (NYSE:OPK) last released its earnings data on Monday, March 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. Analysts expect that Opko Health will post $-0.33 EP
In other Opko Health news, CEO Phillip Md Et Al Frost acquired 6,000 shares of the stock on the open market in a transaction that occurred on Wednesday, March 12th. The shares were purchased at an average price of $9.25 per share, with a total value of $55,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of other analysts have also recently weighed in on OPK. Analysts at Barrington Research raised their price target on shares of Opko Health to $11.00 in a research note on Friday, December 20th. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Opko Health has a consensus rating of “Buy” and a consensus price target of $12.75.
OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national pharmaceutical and diagnostics company.
S for the current fiscal year